SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-311904
Filing Date
2020-12-07
Accepted
2020-12-07 17:23:54
Documents
14
Period of Report
2020-12-07
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d35326d8k.htm   iXBRL 8-K 29063
2 EX-99.1 d35326dex991.htm EX-99.1 26686
6 GRAPHIC g35326dsp007.jpg GRAPHIC 61178
  Complete submission text file 0001193125-20-311904.txt   279536

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sndx-20201207.xsd EX-101.SCH 3063
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sndx-20201207_lab.xml EX-101.LAB 19656
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sndx-20201207_pre.xml EX-101.PRE 12310
7 EXTRACTED XBRL INSTANCE DOCUMENT d35326d8k_htm.xml XML 3619
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 201373566
SIC: 2834 Pharmaceutical Preparations